UCLA Develops AI Platform to Advance Cancer Treatment

The new MAESTRO system identified drug combinations to improve prostate cancer therapy efficacy.

Updated on Oct. 21, 2026 in Cancer

UCLA Develops AI Platform to Advance Cancer Treatment

Live Poll

Do you trust artificial intelligence to accelerate the discovery of effective medical treatments?

UCLA researchers have developed a new artificial intelligence platform called MAESTRO designed to identify effective drug combinations for cancer treatment. By analyzing vast amounts of scientific data, the system successfully pinpointed compounds that could enhance current prostate cancer therapies.

Why it matters

Prostate cancer cells frequently develop resistance to standard treatments by activating alternative biological pathways. This AI-driven approach offers a new method to identify therapies that can overcome this resistance by targeting these secondary pathways.

The MAESTRO platform screened 3,592 natural products to identify 150 high-confidence candidates for testing. Ultimately, 23 compounds showed synergy with enzalutamide across four prostate cancer models.

The players

UCLA

The University of California, Los Angeles, is a public research university that consistently ranks among the top institutions for academic and medical research.

MAESTRO

MAESTRO is an artificial intelligence platform created by researchers to analyze biological data and identify synergistic drug combinations for cancer treatment.

The details

MAESTRO utilizes large language models to analyze scientific knowledge regarding drug mechanisms and cancer cell pathways, evaluating each candidate over 100 times to ensure ranking consistency. Researchers found that a combination of berberine and enzalutamide successfully increased AMPK activity while suppressing mTORC1 signaling.

UCLA announced the development of the MAESTRO platform in October 2026.

The Big Picture

This research follows a pattern set by the National Cancer Institute's Cancer Moonshot initiative to accelerate the development of precision medicine and targeted cancer therapies.

This discovery may eventually lead to more effective treatment options for prostate cancer patients who have developed resistance to existing therapies. Researchers intend to continue evaluating these combinations in patient-derived tumor models and future clinical studies.

The takeaway

Using AI to screen thousands of compounds simultaneously could drastically shorten the timeline for discovering effective drug combinations. Researchers are currently planning to expand the platform's capabilities to test treatments for a wider variety of cancer types.